NPI registry status
Active
2026 NPPES data Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician NPI 1245433259 MD
Verify on CMS → Mark Dacey, MD
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician in Denver, Colorado.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 40 in Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
2K
Medicare Part D claims · 309 beneficiaries · Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician avg: 642
Generic prescribing
67%
generic claims · 33% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
100/100
▲ 17 pts above national avg 83.5 · Exceptional
Industry payments
$119.6K
83 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Mark Dacey, MD reported a CMS MIPS final score of 100/100 - above the 83.5 national average - and filed 1,946 Medicare Part D claims in 2023.
- 100/100
- MIPS score · +17 vs avg
- 2K
- Part D claims, 2023
- 67%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Mark Dacey, MD's MIPS score vs every measured U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure. Clinicians whose score CMS assigned without scoring any category are excluded.
100 ≥ 92nd percentile 92% of 454,083 measured providers are in lower value bands
Each bar is a band; taller bars hold more measured providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative whole-score-point band: it counts only measured clinicians in lower score bands. A CMS MIPS metric is not a recommendation or a clinical-quality rating by PlainDoctor. See methodology § corpus placement.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Mark Dacey, MD sits
This provider among uveitis and ocular inflammatory disease (ophthalmology) physician peers
Across the 20 uveitis and ocular inflammatory disease (ophthalmology) physician providers who report both Medicare Part D prescribing and a MIPS quality score, Mark Dacey, MD writes more Part D claims than 90% of them and scores higher on MIPS quality than 80% - placing this provider in the high-volume, high-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one uveitis and ocular inflammatory disease (ophthalmology) physician peer from a representative sample of 19; the gold marker is Mark Dacey, MD. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
✓
Board certification likely (heuristic, not verified)
Mark Dacey, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Mark Dacey, MD?
High performer (top quartile)Primary specialty
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician
Medicare Part D claims
1,946 203% vs specialty avg
MIPS final score
100/100 16.5 pts vs avg
Specialty distribution in Colorado
How Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician compares to other specialties among Colorado providers
Medicare quality performance, MIPS
Mark Dacey, MD's 2023 MIPS final score plotted against the Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician national average
- MIPS Final Score
- 100/100
- vs 83.5 national avg · 2023 performance year
MIPS final score (Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician) - 100/100 vs national avg 83.5
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Mark Dacey, MD appears in the CMS NPPES registry as a Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician provider holding MD credentials at 425 S CHERRY ST STE 907, Denver, CO, 80246, with a listed phone of (208) 266-4227. NPI 1245433259 was issued on 06/07/2007.
Medicare Part D records for calendar year 2023 show 1,946 prescription claims written by this provider, covering 309 Medicare beneficiaries and totaling roughly $1.4 million in drug spend, split 33% brand-name and 67% generic by claim count. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 100/100 for the 2023 performance year (Quality 100), compared with the 83.5 average among clinicians with a measured score.
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician is a narrow specialty nationwide, with 40 enrolled providers across 17 states and an average of 642 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1245433259 |
|---|---|
| Specialty | Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician |
| Credentials | MD |
| Gender | Male |
| NPI Issued | 06/07/2007 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
100
Final Score
Measured-score avg: 83.5
100
Quality
Reporting: Group practice
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Mark Dacey, MD. Source: openpaymentsdata.cms.gov.
Total received
$119.6K
Largest payer
Alimera Sciences, Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Above average
Mark Dacey, MD - brand share 33.0%
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician average
33% brand-name claims vs 67% generic, on 1,946 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
1,946
Total Claims
$1.4M
Total Drug Cost
309
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 2,913
- Total Day Supply
- 81,390
- Brand vs Generic
- 33% brand / 67% generic
- Brand Drug Cost
- $1.3M
- Generic Drug Cost
- $108K
- Antibiotic Claims
- 18
Patient Demographics
- Average Patient Age
- 72.9 years
- Avg HCC Risk Score
- 1.40
- Gender Split
- 65% female / 35% male
- Age Distribution
- <65: 31, 65-74: 145, 75-84: 105, 85+: 28
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Mark Dacey, MD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Prednisolone Acetate
Prednisolone Acetate
261 claims
- Difluprednate
Difluprednate
205 claims
- Methotrexate
Methotrexate
169 claims
- Timolol Maleate
Timolol Maleate
138 claims
- Mycophenolate Mofe…
Mycophenolate Mofetil
107 claims
- Latanoprost 91
Latanoprost
91 claims
- Brimonidine Tartrate 89
Brimonidine Tartrate
89 claims
- Humira(Cf) Pen 89
Humira(Cf) Pen
89 claims
| Drug | Claims |
|---|---|
| Prednisolone Acetate | 261 |
| Difluprednate | 205 |
| Methotrexate Methotrexate Sodium | 169 |
| Timolol Maleate | 138 |
| Mycophenolate Mofetil | 107 |
| Latanoprost | 91 |
| Brimonidine Tartrate | 89 |
| Humira(Cf) Pen Adalimumab | 89 |
| Prednisone | 87 |
| Valacyclovir Valacyclovir Hcl | 79 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
More Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician in CO →
All providers in Colorado →
Compare specialties →
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Overview
How Mark Dacey, MD fits within the Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician landscape nationally.
40
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Providers in US
17
States with Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician
642
Avg Claims per Provider
Mark Dacey, MD's 1,946 claims are above the specialty average of 642.
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the Colorado medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
How to Find a Doctor
Step-by-step guide to choosing a provider
Verify Credentials
Check NPI, board certification & license status
Medical Specialties Explained
Who treats what and how specialties differ
Understanding Medicare Claims Data
What prescribing data reveals about a provider
In-Network vs Out-of-Network
How insurance networks affect your costs
Telehealth Guide
Virtual care options and coverage in 2026
Explore Colorado
Frequently Asked Questions
What is Mark Dacey, MD's specialty? ▼
Mark Dacey, MD specializes in Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician and practices in Denver, Colorado. Credentials: MD.
How much does Mark Dacey, MD prescribe under Medicare Part D? ▼
In 2023, Mark Dacey, MD wrote 1,946 Medicare Part D claims totaling $1.4M in drug costs for 309 beneficiaries.
What is Mark Dacey, MD's Medicare quality score? ▼
Mark Dacey, MD has a CMS MIPS Final Score of 100/100 (Quality: 100). The average MIPS Final Score across the 454,083 clinicians with at least one published category score is 83.5; clinicians whose score CMS assigned without scoring any category are excluded from that average. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Mark Dacey, MD located? ▼
Mark Dacey, MD is located at 425 S CHERRY ST STE 907, Denver, CO, 80246. Phone: (208) 266-4227.
What is Mark Dacey, MD's NPI number? ▼
Mark Dacey, MD's National Provider Identifier (NPI) is 1245433259, issued on 06/07/2007.
Does Mark Dacey, MD prescribe more brand-name or generic drugs? ▼
Mark Dacey, MD's prescribing is 33% brand-name and 67% generic drugs by claim count, with $1.3M in brand drug costs.
How many Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician providers are there in the US? ▼
There are 40 Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician providers across 17 states in the US. The average Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician provider writes 642 Medicare Part D claims per year.
What drugs does Mark Dacey, MD prescribe most often? ▼
Based on 2023 Medicare Part D data, Mark Dacey, MD's most frequently prescribed drugs include Prednisolone Acetate, Difluprednate, Methotrexate. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Mark Dacey, MD accept Medicare? ▼
Mark Dacey, MD appears in CMS Medicare data with 1,946 Part D claims and 309 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Mark Dacey, MD's credentials? ▼
Mark Dacey, MD's NPI is 1245433259 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.